We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Novel NanoVelcro Chip Isolates Intact Circulating Tumor Cells for Diagnostic Testing

By LabMedica International staff writers
Posted on 27 Jan 2015
An international team of bioengineers has developed a novel "nanoVelcro" device that removes circulating tumor cells (CTCs) from the blood without damaging them.

Samples of CTCs are regarded as the “liquid biopsy” of a tumor, providing convenient access to all disease sites, including primary tumor and fatal metastases. More...
A method that preserves the integrity of CTCs allows molecular and functional analyses that can guide proper therapeutic intervention.

Investigators at the University of California, Los Angeles (USA) and colleagues at RIKEN Advanced Science Institute (Japan) recently described a novel "nanoVelcro" chip that selectively removes CTCs from the blood. The NanoVelcro Chip is about the size of a postage stamp and is composed of nanowires coated with antibodies that recognize CTCs. When two milliliters of blood are passed through the chip, the tumor cells adhere to the nanowires like Velcro. Efficiency of CTC binding ranges from 40% to 70%. The cancer cells are retained by tiny temperature-responsive polymer brushes inside the device. At 37 degrees Celsius, these polymer brushes stick to the tumor cells, but when cooled to four degrees Celsius, they release them, allowing analysis of the cells.

The investigators were able to successfully demonstrate culture expansion and mutational analysis of CTCs isolated by this purification system. In addition, they adopted the combined use of the Thermoresponsive NanoVelcro system with downstream mutational analysis to monitor the disease evolution of an index non-small-cell lung cancer (NSCLC) patient, highlighting its translational value in managing NSCLC.

“With our new system, we can control the blood’s temperature—the way coffeehouses would with an espresso machine—to capture and then release the cancer cells in great purity,” said senior author Dr. Hsian-Rong Tseng, professor of molecular and medical pharmacology at the University of California, Los Angeles. “We combined the thermoresponsive system with downstream mutational analysis to successfully monitor the disease evolution of a lung cancer patient. This shows the translational value of our device in managing non-small-cell lung cancer with underlying mutations.”

A detailed description of the NanoVelcro Chip was published in the December 13, 2014, online edition of the journal ACS Nano.

Related Links:

University of California, Los Angeles
RIKEN Advanced Science Institute



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.